Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Morbidly Obese Patients Undergoing Bariatric Surgery: An open_label Randomized Controlled Trial
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Rivaroxaban versus enoxaparin for prophylaxis of venous thromboembolism in morbidly obese patients undergoing bariatric surgery: An open\_label randomized controlled trial
Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Maximum Age: 60
Healthy Volunteers: t
View:
• Age: 20-60 years, both sexes.
• ASA physical status class I to III.
• BMI 35-50 kg/m²
Locations
Other Locations
Egypt
Alexandria University
RECRUITING
Alexandria
Contact Information
Primary
sarah m elgamal, MD
sarahelgamal1990@yahoo.com
01005496440
Time Frame
Start Date: 2024-10-01
Estimated Completion Date: 2026-05-01
Participants
Target number of participants: 162
Treatments
Active_comparator: group E
81 patients will receive subcutaneous enoxaparin 40 mg every 24 hours starting 12 hours after bariatric surgery for 14 days.
Experimental: group R
81 patients will receive oral rivaroxaban 10 mg once daily starting 24 hours after bariatric surgery for 14 days.
Related Therapeutic Areas
Sponsors
Leads: Alexandria University